IP Library Granted Patent US 12,636,487
Granted Patent B2
US 12,636,487 · App. 17/587,533 · Granted May 26, 2026

Systems and methods for musculoskeletal tissue treatment

Inventors: James T. Ryaby (Lewisville, TX); Erik Waldorff (Lewisville, TX); Ronald Midura (Shaker Heights, OH); Maciej Zborowski (Bay Village, OH)
Assignee: Orthofix US LLC
A61N1/0464A61N1/36014A61N1/36034A61N2/02A61N7/02A61B2018/00005A61B2018/0044A61B2018/00565A61B2018/00791A61N1/0452
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,636,487
App. No.
17/587,533
Granted
May 26, 2026
Kind
B2
Abstract

A system and method for pulsed electromagnetic fields (PEMF) tissue engineering enhances musculoskeletal tissue stimulation. A tissue engineering device may include both low and high pulse frequency signal generation components that may alternatively drive one or more coils to generate PEMFs. These PEMFs may be applied to bone tissue, tendons, ligaments, and/or cartilage. A prescribed treatment regimen using the tissue engineering device may include a first period of time where a first pulse frequency is used in treatment that supports tissue proliferation followed by a second period of time where a second pulse frequency (less than the first pulse frequency) is used in treatment that supports tissue differentiation. A treatment regimen may also include, with the frequency characteristic, applying a slew rate to the pulse characteristics that is on the order of around 30 to 100 Tesla per second to drive tissue differentiation in a targeted manner.

Claims (34)

1 . An apparatus, comprising:

an electromagnetic field transmitter configured to generate a pulsed electromagnetic field, the pulsed electromagnetic field having a slew rate comprising a ratio of change in amplitude of a magnetic field to a time to make the change in amplitude; and

a controller coupled to the electromagnetic field transmitter and configured to:

direct the slew rate of the pulsed electromagnetic field, wherein the slew rate comprises a value between 30 Tesla/second and 100 Tesla/second;

direct a pulse frequency of the pulsed electromagnetic field, wherein the pulse frequency comprises a value between 2 kilohertz and 6 kilohertz; and

maintain a treatment duration of the pulsed electromagnetic field according to a treatment regimen.

2 . The apparatus of claim 1 , wherein the treatment duration includes a time between 30 minutes and 3 hours.

3 . The apparatus of claim 1 , wherein the treatment regimen further includes a burst frequency comprising a value between 10 hertz and 20 hertz.

4 . The apparatus of claim 1 , wherein the treatment regimen further includes a periodicity of treatment, wherein the periodicity of treatment is one day.

5 . The apparatus of claim 1 , wherein the treatment regimen further includes a total duration of treatment between 2 weeks and 6 months.

6 . The apparatus of claim 1 , wherein the controller is further configured to direct an amplitude of the pulsed electromagnetic field, wherein the amplitude comprises a value between 5 milliTesla and 15 milliTesla.

7 . The apparatus of claim 1 , further comprising a sensor configured to monitor a progress of healing of musculoskeletal tissue during operation of the electromagnetic field transmitter.

8 . The apparatus of claim 7 , wherein the controller is further configured to select the pulse frequency in response to the progress of healing identified from the sensor.

9 . An apparatus for tendon tissue repair, comprising:

a controller configured to maintain a slew rate of a pulsed electromagnetic field, the slew rate comprising a ratio of change in amplitude of a magnetic field to a time to make the change in amplitude,

wherein the slew rate comprises a value between 30 Tesla/second and 100 Tesla/second, and wherein the pulsed electromagnetic field comprises a pulse frequency between 2 kilohertz and 6 kilohertz; and

an electromagnetic field transmitter coupled to the controller and configured to generate the pulsed electromagnetic field with the slew rate and the pulse frequency for a treatment of musculoskeletal tissue.

10 . The apparatus of claim 9 , wherein a treatment duration for the treatment of the musculoskeletal tissue includes a time between 30 minutes and 3 hours.

11 . The apparatus of claim 9 , wherein a treatment regimen for the treatment of the musculoskeletal tissue further includes a burst frequency comprising a value between 10 hertz and 20 hertz.

12 . The apparatus of claim 9 , further comprising a sensor configured to monitor a progress of healing of the musculoskeletal tissue during operation of the electromagnetic field transmitter.

13 . The apparatus of claim 12 , wherein the controller is further configured to select the pulse frequency in response to the progress of healing identified from the sensor.

14 . The apparatus of claim 9 , wherein the controller is further configured to direct an amplitude of the pulsed electromagnetic field, wherein the amplitude comprises a value between 5 milliTesla and 15 milliTesla.

15 . The apparatus of claim 9 , wherein a treatment regimen for the treatment of the musculoskeletal tissue further includes a total duration of treatment between 2 weeks and 6 months.

16 . A method for tendon tissue repair, comprising:

receiving, by a controller, an input identifying a treatment mode for application of a pulsed electromagnetic (EM) field (PEMF) to a tendon by an EM field generator;

sending, by the controller, a command to the EM field generator to generate a pulsed EM field in response to the input, the pulsed EM field having a slew rate comprising a value between 30 Tesla/second and 100 Tesla/second and a pulse frequency comprising a value between 2 kilohertz and 6 kilohertz; and

directing, by the controller, the EM field generator to maintain the pulsed EM field with the slew rate and pulse frequency according to a treatment regimen.

17 . The method of claim 16 , wherein the treatment regimen includes a treatment duration between 30 minutes and 3 hours.

18 . The method of claim 16 , further comprising:

comparing, by the controller, a number of times that the EM field generator is energized to a threshold number; and

deactivating, by the controller, the EM field generator in response to the number of times exceeding the threshold number.

19 . The method of claim 16 , wherein the tendon comprises a rotator cuff.

20 . The method of claim 16 , further comprising:

directing an amplitude of the pulsed EM field to a value between 5 milliTesla and 15 milliTesla.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Nov 12, 2024
From: BLUE TORCH FINANCE LLC
To: ISOTIS ORTHOBIOLOGICS, INC.; ORTHOFIX US, LLC; SEASPINE, INC.; SEASPINE ORTHOPEDICS CORPORATION; SPINAL KINETICS LLC; THEKEN SPINE, LLC
Reel/Frame 069358/0110 →
SECURITY INTEREST Recorded Nov 8, 2024
From: ORTHOFIX MEDICAL INC.; ORTHOFIX US LLC; SPINAL KINETICS LLC; SEASPINE ORTHOPEDICS CORPORATION; SEASPINE, INC.; ISOTIS ORTHOBIOLOGICS, INC.; THEKEN SPINE, LLC
To: OXFORD FINANCE LLC, AS AGENT
Reel/Frame 069332/0761 →
SECURITY INTEREST Recorded Jan 10, 2024
From: ORTHOFIX US LLC
To: BLUE TORCH FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 066256/0423 →
ENTITY CONVERSION Recorded Feb 16, 2023
From: ORTHOFIX INC.
To: ORTHOFIX US LLC
Reel/Frame 062769/0265 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 26, 2022
From: MIDURA, RONALD; ZBOROWSKI, MACIEJ
To: CLEVELAND CLINIC FOUNDATION
Reel/Frame 059729/0601 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 26, 2022
From: CLEVELAND CLINIC FOUNDATION
To: ORTHOFIX INC.
Reel/Frame 059730/0707 →
Continuity (4)
Continuation 16876759 · May 18, 2020
Continuation 15870352 · Jan 12, 2018
Provisional Application 62445882 · Jan 13, 2017
Related Publication 20220176101A1 · Jun 9, 2022
References Cited (21)
US 6561968B1 · Dissing · 2003 [cited by examiner]
US 7117034B2 · Kronberg · 2006 [cited by applicant]
US 7951061B2 · Foreman et al. · 2011 [cited by applicant]
US 8137258B1 · Dennis et al. · 2012 [cited by applicant]
US 8376925B1 · Dennis et al. · 2013 [cited by applicant]
US 8795147B1 · Goodwin et al. · 2014 [cited by applicant]
US 9079029B2 · Weinstock · 2015 [cited by examiner]
US 10653881B2 · Ryaby et al. · 2020 [cited by applicant]
US 11235144B2 · Ryaby · 2022 [cited by examiner]
US 20050049689A1 · Gray · 2005 [cited by examiner]
US 20090082613A1 · Dennis et al. · 2009 [cited by applicant]
US 20090287036A1 · Shapiro · 2009 [cited by examiner]
US 20100249488A1 · Kardos · 2010 [cited by examiner]
US 20140148870A1 · Burnett · 2014 [cited by applicant]
US 20140213844A1 · Pilla et al. · 2014 [cited by applicant]
US 20140342428A1 · Goodwin et al. · 2014 [cited by applicant]
DE 102010009743 · 2011 [cited by applicant]
EP 2363168 · 2011 [cited by applicant]
International Searching Authority, Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority or the Declaration—mailed Mar. 28, 2018, Application No.… [cited by applicant]
Australian Patent Office, Examination Report No. 1 for Standard Application, Dated Dec. 17, 2021 for Application No. 2018207572, 3 pages. [cited by applicant]
Canadian Intellectal Property Office, Examiner's Requisition, Dated Oct. 17, 2022 for Application No. 3,048,654, 3 pages. [cited by applicant]